Lumelle A Schneeweis

Title: Lumelle A Schneeweis: Innovator in Antibody Research

Introduction

Lumelle A Schneeweis is a prominent inventor based in Monroe, NJ (US). He has made significant contributions to the field of biochemistry, particularly in the development of innovative antibody therapies. With a total of six patents to his name, Schneeweis has established himself as a key figure in the pharmaceutical industry.

Latest Patents

Schneeweis's latest patents include groundbreaking work on antibodies and antigen binding peptides for factor XIa inhibitors. This invention provides novel antigen binding peptides that specifically bind to selective FXIa inhibitors and dual inhibitors of FXIa and plasma kallikrein. The invention also outlines methods for reducing the antithrombotic effect of FXIa inhibitors by administering a pharmaceutically effective dose of these peptides. Another notable patent focuses on methods of treating inflammation using IL-17A/F and IL-23P19 bispecific antibodies. This invention aims to antagonize the activity of IL-17A, IL-17F, and IL-23 through innovative bispecific antibody formats.

Career Highlights

Schneeweis is currently employed at Bristol-Myers Squibb Company, where he continues to advance his research in antibody development. His work has been instrumental in creating therapies that address critical health issues, particularly in the realm of inflammation and coagulation disorders.

Collaborations

Throughout his career, Schneeweis has collaborated with notable colleagues, including Stanley Richard Krystek, Jr. and Brenda L Stevens. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.

Conclusion

Lumelle A Schneeweis is a distinguished inventor whose work in antibody research has the potential to transform therapeutic approaches in medicine. His contributions to the field are marked by a commitment to innovation and collaboration, making him a valuable asset to the scientific community.